A Thioredoxin Reductase 1 Inhibitor Pyrano [3,2-a] Phenazine Inhibits A549 Cells Proliferation and Migration Through the Induction of Reactive Oxygen Species Production

Overview

Journal Mol Biol Rep

Specialty Molecular Biology

Date 2022 Jul 2

PMID 35780225

Authors

Qifan Ding

Hengyu Wang

Ying Wang

Yuanyuan Lu

Affiliations

Soon will be listed here.

Abstract

Background: Thioredoxin reductase 1 (TrxR1) inhibitor, pyrano [3,2-a] phenazine, named CPUL-1, was synthesized with potential anticancer activity. The aim of the present work was to explore the potential anti-proliferative and anti-metastatic ability of CPUL-1 against A549 cancer cell lines in vitro.

Methods And Results: First, Cell Counting Kit-8 (CCK8) assay was used to assess cell proliferation. The A549 cell migration was evaluated by wound healing assay and transwell assay. Second, the epithelial-mesenchymal transition (EMT)-related proteins in A549 cells treated with CPUL-1 were analyzed by western blot methods. Then, TrxR1 enzyme activity assay and reactive oxygen species (ROS) assay were conducted to evaluate the effect of CPUL-1 on TrxR1 inhibition and ROS levels. Finally, western blotting was used to explore the mechanism of CPUL-1. The study results revealed that the ability of cell proliferation and migration was decreased under CPUL-1 treatment. CPUL-1 could distinctly restrain the migration and invasion of A549 cells through inhibiting EMT process. The results of TrxR1 enzyme activity assay, ROS assay and western blotting showed that CPUL-1 influenced EMT via inducing ROS-mediated ERK/JNK signaling by inhibiting TrxR1 enzyme activity.

Conclusions: Together, proliferation suppression and anti-metastasis activity of CPUL-1 in A549 cells were demonstrated by all the evidence. Our findings highlight the great potential of phenazine compound CPUL-1 to suppress A549 cells proliferation and metastasis.

Citing Articles

PSMD12 promotes non-small cell lung cancer progression through activating the Nrf2/TrxR1 pathway.

Lv J, Ma S, Wang X, Dang J, Ma F Genes Genomics. 2024; 46(3):263-277.

PMID: 38243044 DOI: 10.1007/s13258-023-01484-5.

References

Paracha N, Abdulla A, MacGilchrist K . Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. Health Qual Life Outcomes. 2018; 16(1):179. PMC: 6134713. DOI: 10.1186/s12955-018-0994-8. View

Bunn Jr P, Soriano A, Johnson G, Heasley L . New therapeutic strategies for lung cancer: biology and molecular biology come of age. Chest. 2000; 117(4 Suppl 1):163S-168S. DOI: 10.1378/chest.117.4_suppl_1.163s. View

Molina J, Yang P, Cassivi S, Schild S, Adjei A . Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008; 83(5):584-94. PMC: 2718421. DOI: 10.4065/83.5.584. View

Poullis M, Shackcloth M, Page R, Asanti-Siaw J, Woolley S, Mediratta N . Metastatic index of non-small-cell lung cancer and long-term survival. Asian Cardiovasc Thorac Ann. 2014; 23(2):185-90. DOI: 10.1177/0218492314545833. View

Laursen J, Nielsen J . Phenazine natural products: biosynthesis, synthetic analogues, and biological activity. Chem Rev. 2004; 104(3):1663-86. DOI: 10.1021/cr020473j. View

Zhong Y, Liu J, Cheng X, Zhang H, Zhang C, Xia Z . Design, synthesis and biological evaluations of diverse Michael acceptor-based phenazine hybrid molecules as TrxR1 inhibitors. Bioorg Chem. 2021; 109:104736. DOI: 10.1016/j.bioorg.2021.104736. View

Lu Y, Yan Y, Wang L, Wang X, Gao J, Xi T . Design, facile synthesis and biological evaluations of novel pyrano[3,2-a]phenazine hybrid molecules as antitumor agents. Eur J Med Chem. 2016; 127:928-943. DOI: 10.1016/j.ejmech.2016.10.068. View

Lu Y, Wang L, Wang X, Xi T, Liao J, Wang Z . Design, combinatorial synthesis and biological evaluations of novel 3-amino-1'-((1-aryl-1H-1,2,3-triazol-5-yl)methyl)-2'-oxospiro[benzo[a] pyrano[2,3-c]phenazine-1,3'-indoline]-2-carbonitrile antitumor hybrid molecules. Eur J Med Chem. 2017; 135:125-141. DOI: 10.1016/j.ejmech.2017.04.040. View

Derynck R, Weinberg R . EMT and Cancer: More Than Meets the Eye. Dev Cell. 2019; 49(3):313-316. PMC: 7672963. DOI: 10.1016/j.devcel.2019.04.026. View

10.

Lamouille S, Xu J, Derynck R . Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014; 15(3):178-96. PMC: 4240281. DOI: 10.1038/nrm3758. View

11.

Yang F, Yu N, Wang H, Zhang C, Zhang Z, Li Y . Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9. PLoS One. 2018; 13(1):e0190725. PMC: 5754131. DOI: 10.1371/journal.pone.0190725. View

12.

Zwergel C, Czepukojc B, Evain-Bana E, Xu Z, Stazi G, Mori M . Novel coumarin- and quinolinone-based polycycles as cell division cycle 25-A and -C phosphatases inhibitors induce proliferation arrest and apoptosis in cancer cells. Eur J Med Chem. 2017; 134:316-333. DOI: 10.1016/j.ejmech.2017.04.012. View

13.

Wild C . The global cancer burden: necessity is the mother of prevention. Nat Rev Cancer. 2019; 19(3):123-124. DOI: 10.1038/s41568-019-0110-3. View

14.

Monsuez J, Charniot J, Vignat N, Artigou J . Cardiac side-effects of cancer chemotherapy. Int J Cardiol. 2010; 144(1):3-15. DOI: 10.1016/j.ijcard.2010.03.003. View

15.

Shukla S, Ohnuma S, Ambudkar S . Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets. 2010; 12(5):621-30. PMC: 3401946. DOI: 10.2174/138945011795378540. View

16.

Newman D, Cragg G . Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod. 2016; 79(3):629-61. DOI: 10.1021/acs.jnatprod.5b01055. View

17.

Sangodkar J, Katz S, Melville H, Narla G . Lung adenocarcinoma: lessons in translation from bench to bedside. Mt Sinai J Med. 2010; 77(6):597-605. DOI: 10.1002/msj.20226. View

18.

Avelino C, Cardoso R, de Aguiar S, da Silva M . Assessment of quality of life in patients with advanced non-small cell lung carcinoma treated with a combination of carboplatin and paclitaxel. J Bras Pneumol. 2015; 41(2):133-42. PMC: 4428850. DOI: 10.1590/S1806-37132015000004367. View

19.

Li S, Fu H, Wang Y, Wang L, Jia B, Bian Y . Curcumin inhibits CT26 cells metastasis by decreasing heparanase expression. J Leukoc Biol. 2020; 108(6):1727-1733. DOI: 10.1002/JLB.1MA0620-357R. View

20.

Sung J, Park S, Kim J, Kang H, Yoon J, Na Y . Interferon consensus sequence-binding protein (ICSBP) promotes epithelial-to-mesenchymal transition (EMT)-like phenomena, cell-motility, and invasion via TGF-β signaling in U2OS cells. Cell Death Dis. 2014; 5:e1224. PMC: 4047854. DOI: 10.1038/cddis.2014.189. View